NUVL Stock Analysis: Buy, Sell, or Hold?
NUVL - Nuvalent, Inc. Class A Common Stock
$99.07
-3.23 (-3.16%)
▼
5d:
-5.24%
30d:
-7.94%
90d:
-3.1%
HOLD
LOW Confidence
Analysis Updated: May 18, 2026 12:00 AM ET
Earnings: May 14, 2026
0d
Get Alerted When NUVL Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: NUVL shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: NUVL shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: NUVL is currently trading at $99.07, which is considered oversold relative to its 30-day fair value range of $101.21 to $106.47.
Technical Outlook: Technically, NUVL is showing sideways momentum. The price is currently testing key support at $99.36. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.2% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $142.06 (+38.9%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, NUVL is showing sideways momentum. The price is currently testing key support at $99.36. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.2% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $142.06 (+38.9%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$101.21 -
$106.47
Company Quality Score
56/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.2%)
- BULLISH: Trading 38.9% below Wall St target ($142.06)
- CAUTION: Recommendation downgraded due to -5.2% 5-day decline
Trading Range Analysis
30-Day Trading Range
$101.21 -
$106.47
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$99.36
Resistance Level
$109.11
Current Trend
Sideways
Technical data as of
May 18, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-24.25
Wall Street Target
$142.06
(+38.9%)
Share & Embed Analysis
Last updated: May 18, 2026 1:51 PM ET
Data refreshes hourly during market hours. Next update: 2:51 PM
Data refreshes hourly during market hours. Next update: 2:51 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NUVL showing a specific setup today?
Insider Activity (6 Months)
0
Buys
19
Sells
Net
INSIDERS SELLING
Recent Transactions
Henry E Pelish
SELL
3093 shares
2026-04-09
James Richard Porter
SELL
30000 shares
2026-04-06
Alexandra Balcom
SELL
11430 shares
2026-04-01
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$27 | 52 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$411 | 53 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$270 | 61 BUY |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$83 | 57 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$109 | 58 HOLD |
